Nuvation Bio, Inc. (NUVB)
4.45
-0.30
(-6.32%)
USD |
NYSE |
Oct 16, 16:00
4.46
+0.01
(+0.22%)
After-Hours: 20:00
Nuvation Bio Cash from Operations (Quarterly) : -42.97M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -42.97M |
| March 31, 2026 | 5.069M |
| December 31, 2025 | -29.73M |
| September 30, 2025 | -52.89M |
| June 30, 2025 | -48.18M |
| March 31, 2025 | -42.63M |
| December 31, 2024 | -46.30M |
| September 30, 2024 | -31.08M |
| June 30, 2024 | -37.32M |
| March 31, 2024 | -15.70M |
| December 31, 2023 | -15.03M |
| September 30, 2023 | -16.16M |
| June 30, 2023 | -17.48M |
| Date | Value |
|---|---|
| March 31, 2023 | -19.33M |
| December 31, 2022 | -16.17M |
| September 30, 2022 | -28.09M |
| June 30, 2022 | -26.92M |
| March 31, 2022 | -24.93M |
| December 31, 2021 | -23.48M |
| September 30, 2021 | -13.15M |
| June 30, 2021 | -16.83M |
| March 31, 2021 | -14.73M |
| December 31, 2020 | -12.94M |
| September 30, 2020 | -8.038M |
| June 30, 2020 | -6.836M |
| March 31, 2020 | -8.718M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | 3.393B |
| Johnson & Johnson | -- |
| Pfizer Inc. | 835.00M |
| Eli Lilly & Co. | 10.69B |
| Merck & Co., Inc. | 5.37B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 5.991M |
| Cash from Financing (Quarterly) | 170.53M |
| Free Cash Flow | -128.92M |
| Free Cash Flow Per Share (Quarterly) | -0.1239 |
| Free Cash Flow to Equity (Quarterly) | -242.50M |
| Free Cash Flow to Firm (Quarterly) | -36.46M |
| Free Cash Flow Yield | -8.20% |